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Guidelines for the Use of Fluralaner (‘Bravecto® Spot-on 
Solution for Dogs’) to Treat Sarcoptic Mange in Wombats 
 
This information sheet was prepared by the research team at the University of Tasmania, taking into account input 
from a range of stakeholders.  
 
Pending the issuing of an APVMA permit for Bravecto®, the purpose of this sheet is to assist treaters and 
veterinarians who have chosen to use Bravecto® by providing them with up-to-date information that is based on 
the best available evidence from current research. As such, the information provided within is an accurate 
representation of what is presently known and not known regarding the use of fluralaner to treat sarcoptic mange 
in wombats. This information sheet will be updated as knowledge grows through scientific research and field 
experience (see page footer for the location of the most up-to-date version).  
 
Drug Fluralaner 
Description: systemic insecticide (anti-insect activity) and acaricide (anti-mite activity) 
belonging to the isoxazoline class of drugs 
Product Bravecto® Spot-on Solution for Dogs (MSD Animal Health) 
Active ingredient: 280 mg/ml Fluralaner 
Solvent: 339 mg/ml Dimethylacetamide (d-limonene) 
Description: veterinary medication used to control a range of external and internal parasites in 
dogs and cats 
Background Fluralaner, which has been scientifically proven to kill all lifecycle stages of the mange mite 
(Sarcoptes scabiei), including the eggs, is commercially available in the form of the veterinary 
medication, Bravecto®. 
 
Researchers at the University of Tasmania have tested fluralaner for the treatment of sarcoptic 
mange in the bare-nosed wombat (common wombat, Vombatus ursinus), using the Bravecto® 
formulation. Safety trials confirmed that fluralaner/Bravecto® is safe to use in both adult and 
juvenile wombats when using the doses recommended below. Efficacy trials found that a single 
dose resulted in complete resolution of the clinical signs (symptoms) of sarcoptic mange in adult 
and juvenile wombats within 4 weeks of treatment, and provided protection from re-infestation 
with mange mites and other ectoparasites for up to 3 months. Field trials in wild bare-nosed 
wombats are ongoing.  
Authorisation 
Status 
Until an APVMA permit has been issued, Bravecto® can only be used to treat wombats under the 
direct supervision of a veterinarian as it is an ‘off label’ treatment. (N.B. The degree of 
supervision is at the discretion of the supervising veterinarian). 
 
It is also important that treaters comply with jurisdictional rules and acquire licences or permits 
as required by State and Territory agencies. 
Dosage and 
Frequency 
Bravecto® Spot-On for Large Dogs is the most appropriate product size for adult wombats. 
Further information below: 
 
Guidelines for the Use of Fluralaner (‘Bravecto® Spot-on Solution for Dogs’) to Treat Sarcoptic Mange in Wombats Page 2 of 4 
















1. The Recommended doses should be sufficient to resolve mange in bare-nosed wombats.  
2. The Maximum dose guidelines apply if there is concern about treatment response or if an 







Product to Use 
Safe administration frequency 
5 – 10kg Joey Bravecto® Spot-on 
for Small Dogs 
(1 x 0.89ml pipette) 
Recommended: Once1 
 
Maximum: Once per month for up 
to 3 months2 
10 – 20kg Large joey or 
small adult 
Bravecto® Spot-On 
for Medium Dogs 
(1 x 1.79ml pipette) 
20 – 40kg Adult Bravecto® Spot-On 
for Large Dogs 
(1 x 3.57ml pipette) 
Application  Spot-on: When treating wombats in care, the dose can be given as a spot-on by parting the fur 
and applying directly to the skin on the neck or between the shoulder blades. For Large Dog 
pipettes, the dose can be applied at a single location or at two or three points on the neck and 
upper back (avoiding the rump), as per the manufacturer’s instructions. This is to avoid the 
treatment dripping or running off the application site.  
 
Pour-on: When treating wombats in the wild, the dose can be applied as a pour-on treatment 
via burrow flap or with a pole-and-scoop to the wombat’s back, aiming for skin that is 
unaffected by mange. Because the dose is tiny, it may require a carrier (dilutant). The most 
appropriate carrier is approximately 5-20ml of Orange Power Sticky Spot & Goo Dissolver (Aware 
Environmental Products), available at most supermarkets.  (See explanatory notes below in the 
FAQs).  
Note: Mixing Bravecto® with Cydectin®/moxidectin, is not recommended because: 
1. Bravecto® has been shown to be highly efficacious when used singularly 
2. The impact of giving multiple drugs to wombats is not currently understood. There may 
be serious consequences for health and recovery, particularly for individuals in poor 
condition 
3. Anecdotal results from combination treatments suggest that therapeutic doses of 
Bravecto® may not have been delivered effectively when mixed with Cydectin® 
Refer to the manufacturer’s guidelines regarding handling and personal protective equipment. 
FAQs 1. Q: Does fluralaner cure mange in wombats? 
A: In scientific trials, all wombats treated with a recommended dose of fluralaner showed 
complete recovery from mange within four weeks of treatment. Although there are reports 
of incomplete recovery following treatment with Bravecto® products, we suspect that these 
cases are most likely due to drug delivery failure and the wombat receiving only a partial 
dose.  
 
2. Q: Is it appropriate to use Bravecto on wombats affected with mange at all stages of 
infection, included seriously debilitated individuals? 
A: Wombats with severe mange are often suffering from secondary disease complications. 
Such animals are unlikely to recover despite treatment, and euthanasia may be necessary 
for animal welfare reasons. Although it can be difficult to tell how severely affected an 
animal is, if one or more of the following are observed then euthanasia should be 
considered: 
− The wombat is extremely thin/emaciated 
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− Presence of infected/smelly wounds or excessive fly activity/fly strike 
− Apparent blindness (due to severe facial crusting), difficulty breathing or eating 
− Signs of weakness or incoordination 
− Hair loss and skin crusting/scabs affecting 50% or more of the side of the animal 
If you are unsure as to whether euthanasia is required, contact your veterinary surgeon.  
 
3. Q: Is Bravecto® safe to use in female wombats with pouch young or a joey-at-foot? 
A: Scientific trials safely tested Bravecto® in wombats as young as 10 months old. Although 
it is possible that variation between species exists, evidence from several species of 
domestic animal suggests that fluralaner is also unlikely to pose a health risk to developing 
wombat embryos or nursing young.    
 
4. Q: When is it safe to give another dose of Bravecto® to a wombat? 
(i) If only part of the treatment was delivered during application, when can the wombat be 
re-treated to ensure it gets a full treatment dose? 
(ii) If the wombat does not appear to be responding to treatment, when is the right time to 
apply further treatment? 
A: Scientific trials show that a single recommended dose of fluralaner is sufficient to treat 
mange and protect from reinfestation for approximately three months. As such, multiple 
doses should not be required. However, evidence from safety trials has also shown that 
fluralaner has a wide safety margin and may be administered at a maximum frequency of 
once per month for up to 3 months, where justified. 
(i) As such, if there is concern regarding incomplete drug administration, it is safe to re-
attempt treatment with the recommended dose (provided that the maximum 
administration frequency is not exceeded, see table above).   
(ii) If there is concern that the affected animal is not responding to treatment, consult with 
your supervising veterinarian. They may recommend re-attempting treatment (provided 
that the maximum administration frequency is not exceeded, see table above). 
N.B. Treating wombats with Bravecto® for more than 3 months is not recommended 
because: 
− Both the ‘Recommended’ and ‘Maximum’ treatment regimes specified in the table 
above should result in the resolution of sarcoptic mange in wombats. If this is not the 
case, refer to Q10 below.  
− Prolonged or excessive use of pharmacological compounds in wild animals can promote 
drug resistance in the parasite, adverse health consequences for the host, and result in 
adverse environmental impacts. 
 
5. Q: Can the treatment still be applied if 
(i) The wombat to be treated is wet from rain, or  
(ii) rain is forecast shortly after the intended time of treatment.  
A: (i) The effect of wet skin or fur on the ability of any mange treatment to reach the skin 
and be absorbed is unknown. As a matter of precaution, and to avoid any potential 
interference, treatments should be applied to dry animals wherever possible.  
(ii) Pharmacokinetic data from wombats and other species shows that fluralaner is rapidly 
absorbed through the skin into the blood stream, suggesting that coat-wetting following 
drug application is unlikely to interfere with treatment. However, if heavy rain is forecast in 
the 72 hours following treatment, it is advisable to postpone drug application until drier 
weather is forecast to lower any risk of reduced drug absorption.  
 
6. Q: How and why was Orange Power chosen as the carrier for pour-on application?   
A: Interdisciplinary scientific evaluation (including by chemical and veterinary specialists) 
deemed that the most appropriate carrier is Orange Power Sticky Spot & Goo Dissolver 
(Aware Environmental Products). The rationale for using Orange Power is that:  
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− It does not interact pharmacologically with fluralaner  
− Its ingredients are similar to the solvent in Bravecto® and not harmful to wombats  
− It mixes readily with Bravecto® into a solution that will not separate 
− It is inexpensive and readily available in most supermarkets. 
 
7. Q: 5-20ml of Orange Power doesn’t sound like enough carrier fluid. Can this volume be 
increased?   
A: Increasing the volume of the carrier above 20ml is not recommended. This is to reduce 
the risk of losing any fluralaner by dripping or running off the wombat. In trials we have 
found this volume to penetrate through the fur of wombats to the skin. 
 
8. Q: Won’t the smell of Orange Power be a deterrent to wombats? 
A: The product has an orange scent that is of similar intensity to the smell of Bravecto® itself 
and is therefore unlikely to contribute additional sensory impact on the wombat. It is worth 
noting that wombats can exhibit aversion to other treatments as well and can avoid or 
destroy burrow flaps regardless of the type of treatment. 
 
9. Q: If the dose has already been dispensed into a pole-and-scoop device but the wombat 
evades treatment, can the dose be retained for future use? 
A: As per the manufacturer’s guidelines, Bravecto® should not be removed from its pipette 
until ready for use. Once removed from the manufacturer’s packaging, the lifespan of the 
product is unknown but is likely to be less than 7 days. If storage is required, keeping the 
contents in a dark plastic or glass container away from direct sunlight is considered 
appropriate, but not guaranteed to be effective.   
 
10. Q: Adverse effects have been observed following treatment administration. What should be 
done? 
A: In the event of any suspected adverse effects or incomplete response to treatment, 
contact your supervising veterinarian as soon as possible. Such reports should also be sent 
to the UTAS research team by the veterinarian or the treater to contribute to further 
research on the safety and efficacy of Bravecto® as a treatment for mange in wombats. 
Further 
Reading 
Wilkinson V, Takano K, Nichols D, Martin A, Holme R, Phalen D, Mounsey K, Charleston M, Kreiss 
A, Pye R, Browne E. Fluralaner as a novel treatment for sarcoptic mange in the bare-nosed 
wombat (Vombatus ursinus): safety, pharmacokinetics, efficacy and practicable use. Parasites & 
Vectors. 2021 Dec;14(1):1-21. 
Sarcoptic mange in Australian wildlife. Wildlife Health Australia factsheet (May 2017) 
Van Wick M and Hashem B. (2019) Treatment of Sarcoptic Mange in an American Black Bear 
(Ursus americanus) with a Single Oral Dose of Fluralaner. Journal of Wildlife Diseases: January 
2019, Vol. 55, No. 1, pp. 250-253.  
Taenzler J, Liebenberg J, Roepke RK, Frenais R, Heckeroth AR. Efficacy of fluralaner administered 
either orally or topically for the treatment of naturally acquired Sarcoptes scabiei var. canis 
infestation in dogs. Parasites and Vectors. 2016;9(1):392. 
Curtis CF, Bourdeau PJ, Barr PA, Mukherjee R. Use of the novel ectoparasiticide fluralaner in the 
treatment of feline sarcoptic mange. Veterinary Record Case Reports. 2019;7(1):e000772. 
Contact 
 
For further information, contact the research team at the University of Tasmania:  
Dr Scott Carver, scott.carver@utas.edu.au 
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